{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:01:35Z","timestamp":1785391295120,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunoglobulin light chain (AL) amyloidosis and POEMS syndrome are plasma cell proliferative disorders involving multiple organs and tissues, often presenting with nonspecific clinical manifestations. The co-occurrence of both conditions in a single patient is clinically rare and can easily lead to misdiagnosis or underdiagnosis. This report describes an elderly male patient who presented primarily with refractory heart failure and was ultimately diagnosed with coexisting AL amyloidosis and POEMS syndrome. The patient received 12 cycles of treatment with bortezomib, cyclophosphamide, and dexamethasone (BCD), achieving significant clinical and biochemical remission. This case underscores that while the coexistence of rare diseases is uncommon, it represents an important cause of clinical complexity and treatment resistance. A comprehensive etiological diagnosis is therefore a crucial prerequisite for formulating an effective and individualized treatment plan.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1771265","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:39:24Z","timestamp":1785389964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A rare coexistence of immunoglobulin light chain amyloidosis and POEMS syndrome manifesting as refractory heart failure: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Meixian","family":"Lei","sequence":"first","affiliation":[{"name":"Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]},{"name":"Department of Cardiology, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"He","sequence":"additional","affiliation":[{"name":"Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]},{"name":"Department of Cardiology, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]},{"name":"Department of Cardiology, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]},{"name":"Department of Cardiology, Jiujiang No. 1 People\u2019s Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-na\u00efve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198007000-00006","article-title":"Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature","volume":"59","author":"Bardwick","year":"1980","journal-title":"Medicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0586","article-title":"Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review","volume":"7","author":"Khouri","year":"2021","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.0.CO;2-4","article-title":"Overproduction of vascular endothelial growth factor\/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome","volume":"21","author":"Watanabe","year":"1998","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.56.6.807","article-title":"Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMSsyndrome","volume":"56","author":"Michizono","year":"2001","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23288","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.344","article-title":"Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment","volume":"30","author":"Kourelis","year":"2016","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","article-title":"Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience","volume":"120","author":"D'souza","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0391-2","article-title":"What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone","volume":"33","author":"Zhao","year":"2019","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5045\/br.2022.2022001","article-title":"Update on the POEMS syndrome","volume":"57","author":"Kim","year":"2022","journal-title":"Blood Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/hci.0000000000000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1800","article-title":"Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients","volume":"133","author":"Allam","year":"2008","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.073031","article-title":"Pulmonary hypertension in POEMS syndrome","volume":"98","author":"Li","year":"2013","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.2833","article-title":"Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide","volume":"49","author":"Inoue","year":"2010","journal-title":"Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.03.010","article-title":"Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome","volume":"50","author":"Jang","year":"2018","journal-title":"Pathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/nejmoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24356","article-title":"Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14497","article-title":"Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen","volume":"181","author":"He","year":"2018","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01780.x","article-title":"Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS","volume":"88","author":"Warsame","year":"2012","journal-title":"Eur J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2842-19","article-title":"POEMS syndrome showing left ventricular dysfunction and extracellular edema assessed by cardiac magnetic resonance imaging","volume":"58","author":"Takahashi","year":"2019","journal-title":"Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytab504","article-title":"POEMS syndrome causing left ventricular hypertrophy, myocardial dysfunction, and pericardial effusion: a case report","volume":"6","author":"Wang","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21581","article-title":"Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course","volume":"85","author":"Adami","year":"2010","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.15-038","article-title":"Cardiac involvement in a patient with POEMS syndrome detected using cardiac magnetic resonance imaging","volume":"56","author":"Pei","year":"2015","journal-title":"Int Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.21037\/atm-21-1071","article-title":"Congestive heart failure associated with POEMS syndrome that was adequately distinguished from cardiac amyloidosis: a case report and literature review","volume":"9","author":"Hagiwara","year":"2021","journal-title":"Ann Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.9256","article-title":"Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome","volume":"52","author":"Yokokawa","year":"2013","journal-title":"Intern Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:39:25Z","timestamp":1785389965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1771265"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771265","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1771265"}}